You are here : Home > NeurATRIS : European Advanced Translational Research Infrastructure for Neurosciences


NeurATRIS : European Advanced Translational Research Infrastructure for Neurosciences

Published on 30 January 2015
NeurATRIS is a National Infrastructure in Biology and Health that coordinates translational research in the neurosciences. Thanks to the complementarity of their expertise, platforms and knowledge, its members, all experts in biotherapy and neuroscience, contribute to strengthening exchanges between academic, clinical and industry research, to catalyze the emergence of key scientific and technological breakthroughs.
NeurATRIS is the French contribution to EATRIS, a European infrastructure for translational research. It represents a specialized component in neurosciences and neurology, as detailed by ESFRI, the European roadmap of research infrastructures.

Its missions

  • Develop knowledge and specific lines of neuroscience research to discover and validate innovative therapeutic approaches for neurodegenerative and neurodevelopmental disorders
  • Gather specialists from varied and complementary scientific disciplines to foster an exchange of expertise far from within a single structure 
  • Provide researchers from academic, clinical and industrial communities access to an infrastructure and teams of the highest level, to support and implement their translational research projects in the neurosciences


Partners and organization

NeurATRIS brings together 5 research centers of scientific and technical excellence in translational research:

  • Institute of Biomedical Imaging (CEA-I2BM)
  • ICM - Brain and spine institute
  • The hôpital Bicêtre at Kremlin-Bicêtre
  • Institute for Biotherapy of Rare Diseases (AFM-Téléthon-Inserm) at Évry (BIRD)
  • The hôpital Henri Mondor at Créteil

NeurATRIS at the CEA

The DSV teams involved in NeurATRIS are part of the CEA-I2BM. They are attached to the Service Hospitalier Frédéric Joliot, NeuroSpin and MIRCen. They are specialized in:

  • Clinical and preclinical molecular and functional imaging
  • The development of high-field imaging technologies
  • Gene and cell therapy for treating neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease)
P.Stroppa/CEASetting up an imaging experiment on a small animal, using preclinical MRI (7 teslas) at MIRCen, in the CEA center of Fontenay-aux-Roses. The protocols developed to test the effectiveness of a treatment in an animal model are directly transferable to humans, making it possible to accelerate the test phase. © P.Stroppa/CEA





  • Philippe Hantraye, director of the preclinical research center at the MIRCen of CEA-I2BM/INSERM
  • Bernard Zalc, research director at ICM - Brain and spine institute


Top page